arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Oric Pharmaceuticals, Inc.

ORIC
$13.51 ▲ +0.85 (+6.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Oric Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -9.4%
FCF / Share $-0.30
Trailing P/E
Price / Book 3.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-41.49M
↓ -14.1%
FCF / Share Free cash flow per share
$-0.30
↑ +3.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters